title: Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome.
abstract: BACKGROUND
  Disseminated infection with Mycobacterium avium is common with late-stage acquired immunodeficiency syndrome (AIDS), and no antimicrobial agent has been found to be clearly effective.
  
  
  METHODS
  A multicenter open trial was conducted to assess the antimicrobial activity and clinical efficacy of clarithromycin--a new macrolide antibiotic--against disseminated M avium in 77 patients with late-stage AIDS. Blood cultures were taken at baseline and during treatment; side effects were also evaluated.
  
  
  RESULTS
  Mycobacterium avium was eradicated from blood cultures in 11 (63%) of 16 evaluable patients receiving daily doses or 500 or 1000 mg, (n = 21) and in 45 of 46 (98%) of those receiving 1500 or 2000 mg (n = 56). Eradication after 2 months was influenced by continuity of drug treatment; 36 of 42 patients with no relapse had received continuous treatment vs six of 14 patients whose drug treatment had been stopped for 7 days or longer. After 2 to 7 months of treatment, acquired resistance associated with relapse was observed. Drug side effects were elevated liver enzyme levels (26%) and impaired hearing (4%). Concomitant AIDS drugs had no favorable effect on outcome and may have worsened liver toxicity.
  
  
  CONCLUSIONS
  Clarithromycin has bacteriologic efficacy against M avium infection in late-stage AIDS, although drug resistance eventually develops. Further studies are needed to investigate safe, effective concomitant drugs.
authors.affiliation: Pulmonary Department, Groupe Hospitalier, Pitié-Salpêtrière, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Dautzenberg
authors.forename: T
authors.initials: T
authors.lastname: Saint Marc
authors.forename: M C
authors.initials: MC
authors.lastname: Meyohas
authors.forename: M
authors.initials: M
authors.lastname: Eliaszewitch
authors.forename: F
authors.initials: F
authors.lastname: Haniez
authors.forename: A M
authors.initials: AM
authors.lastname: Rogues
authors.forename: S
authors.initials: S
authors.lastname: De Wit
authors.forename: L
authors.initials: L
authors.lastname: Cotte
authors.forename: J P
authors.initials: JP
authors.lastname: Chauvin
authors.forename: J
authors.initials: J
authors.lastname: Grosset
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000009:adverse effects / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D017291:Clarithromycin